Phytocannabinoids and epilepsy
R.G. dos Santos,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak,João Pereira Leite,Antonio Waldo Zuardi,Antonio Waldo Zuardi,José Alexandre de Souza Crippa,José Alexandre de Souza Crippa +7 more
TLDR
Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects than available antiepileptic drugs.Abstract:
SUMMARY What is known and objective: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects than available antiepileptic drugs. The present review summarizes studies on the anticonvulsant properties of phytocannabinoids. Methods: Literature search using the PubMed database to identify studies on phytocannabinoids and epilepsy. Results and discussion: Preclinical studies suggest that phytocannabinoids, especially cannabidiol and cannabidivarin, have potent anticonvulsant effects which are mediated by the endocannabinoid system. Human studies are limited in number and quality, but suggest that cannabidiol has anticonvulsant effects in adult and infantile epilepsy and is well tolerated after prolonged administration. What is new and conclusion: Phytocannabinoids produce anticonvulsant effects through the endocannabinoid system, with few adverse effects. Cannabidiol and cannabidivarin should be tested in randomized, controlled clinical trials, especially in infantile epileptic syndromes.read more
Citations
More filters
Journal ArticleDOI
A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis
TL;DR: The approach for phytocannabinoid profiling can enable researchers and physicians to analyze the effects of specific Cannabis compositions and is therefore critical when performing biological, medical and pharmacological-based research using Cannabis.
Journal ArticleDOI
Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise.
Charu Sharma,Juma Al Kaabi,Syed M. Nurulain,Sameer N. Goyal,Mohammad Amjad Kamal,Shreesh Ojha +5 more
TL;DR: A comprehensive insight is provided of pharmacological and therapeutic potential of BCP, its molecular mechanism and signaling pathways in different pathological conditions and the possibility of its further development as a novel candidate for various pathologies considering the polypharmacological and multifaceted therapeutic properties potential.
Journal ArticleDOI
Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence
Emily Stockings,Dino Zagic,Gabrielle Campbell,Megan Weier,Wayne Hall,Suzanne Nielsen,Geoffrey K. Herkes,Michael Farrell,Louisa Degenhardt +8 more
TL;DR: Drug-grade CBD as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency and quality of life; RCTs examining other syndromes and cannabinoids are needed.
Journal ArticleDOI
Targeting the endocannabinoid system: future therapeutic strategies
Oier Aizpurua-Olaizola,Izaskun Elezgarai,Irantzu Rico-Barrio,Iratxe Zarandona,Nestor Etxebarria,Aresatz Usobiaga +5 more
TL;DR: This review of the latest studies regarding the role of the ECS and the drugs that target it highlights the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics toward the development of improved and more specific drugs for each relevant disease.
Journal ArticleDOI
The Pharmacological Basis of Cannabis Therapy for Epilepsy
TL;DR: The pharmacological basis of cannabis therapy is highlights, with an emphasis on the endocannabinoid mechanisms underlying the emerging neurotherapeutics of CBD in epilepsy, and a rigorous clinical evaluation of pharmaceutical CBD products is needed to establish the safety and efficacy of their use in the treatment of epilepsy.
References
More filters
Journal ArticleDOI
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Orrin Devinsky,Maria Roberta Cilio,Helen Cross,Javier Fernández-Ruiz,Jacqueline A. French,Charlotte L Hill,Russell Katz,Vincenzo Di Marzo,Didier Jutras-Aswad,William George Notcutt,José Martínez-Orgado,Philip Robson,Brian G. Rohrback,Elizabeth A. Thiele,Benjamin J. Whalley,Daniel Friedman +15 more
TL;DR: CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.
Journal ArticleDOI
The endocannabinoid system controls key epileptogenic circuits in the hippocampus.
Krisztina Monory,Federico Massa,Federico Massa,Michaela Egertová,Matthias Eder,Heike Blaudzun,Ruth E. Westenbroek,Wolfgang Kelsch,Wolfgang Jacob,Rudolf Marsch,Marc Ekker,Jason E. Long,John L.R. Rubenstein,Sandra Goebbels,Klaus-Armin Nave,Matthew J. During,Matthias Klugmann,Barbara Wölfel,Hans-Ulrich Dodt,Walter Zieglgänsberger,Carsten T. Wotjak,Ken Mackie,Maurice R. Elphick,Giovanni Marsicano,Giovanni Marsicano,Beat Lutz +25 more
TL;DR: The direct endocannabinoid-mediated control of hippocampal glutamatergic neurotransmission may constitute a promising therapeutic target for the treatment of disorders associated with excessive excitatory neuronal activity.
Journal ArticleDOI
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Jomar M. Cunha,Elisaldo Araujo Carlini,Aparecido E. Pereira,Oswaldo L. Ramos,Camilo Pimentel,Rubens Gagliardi,Wilson Luiz Sanvito,N. Lander,Raphael Mechoulam +8 more
TL;DR: Four of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition, while CBD was ineffective in 1 patient.
Journal ArticleDOI
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders Report of the Guideline Development Subcommittee of the American Academy of Neurology
Barbara S. Koppel,John C.M. Brust,Terry D. Fife,Jeff M. Bronstein,Sarah Youssof,Gary S. Gronseth,David Gloss +6 more
TL;DR: A systematic review of medical marijuana to address treatment of symptoms of multiple sclerosis, epilepsy, and movement disorders found oral cannabinoids are of unknown efficacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy.
Journal ArticleDOI
Cannabinoids in medicine: A review of their therapeutic potential.
TL;DR: Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases, analgesics, and in the treatment of multiple sclerosis, spinal cord injuries, Tourette’s syndrome, epilepsy and glaucoma.
Related Papers (5)
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky,Eric D. Marsh,Daniel Friedman,Elizabeth A. Thiele,Linda Laux,Joseph Sullivan,Ian Miller,Robert Flamini,Angus Wilfong,Francis Filloux,Matthew Wong,Nicole Tilton,Patricia L. Bruno,Judith Bluvstein,Julie Hedlund,Rebecca M. Kamens,Jane Maclean,Srishti Nangia,Nilika S. Singhal,Carey A Wilson,Anup D. Patel,Maria Roberta Cilio +21 more